drugset / Trial / NCT01946373

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

NCT01946373

Phase 1 Unknown 20 enrolled Karolinska University Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to learn if dendritic cell vaccine will increase the effect of tumor infiltrating lymphocytes given with chemotherapy and interleukin-2 in patients with melanoma.

Timeline

Start
2013-10
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject DC vaccine Vaccine 1.5e+07 cells Intramuscular
Subject T cells Cell therapy 5e+10 cells Intravenous
Background Cyclophosphamide Other / unclassified 60 mg/kg Intravenous
Background Fludarabine Small molecule 25 mg/m2 Intravenous
Background aldesleukin Protein / enzyme biologic 100000 iu/kg Intravenous

Indications